BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 22169963)

  • 1. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
    De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
    Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
    De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
    Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating the thyroid in the presence of Graves' ophthalmopathy.
    Hegedüs L; Bonnema SJ; Smith TJ; Brix TH
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):313-24. PubMed ID: 22632368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
    Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
    Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
    [No Abstract]   [Full Text] [Related]  

  • 6. Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial.
    Moleti M; Violi MA; Montanini D; Trombetta C; Di Bella B; Sturniolo G; Presti S; Alibrandi A; Campennì A; Baldari S; Trimarchi F; Vermiglio F
    J Clin Endocrinol Metab; 2014 May; 99(5):1783-9. PubMed ID: 24432992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of TSH receptor autoantibodies for the diagnosis of Graves' disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. Recommendations of the Thyroid Section of the German Society of Endocrinology].
    Eckstein A; Mann K; Kahaly GJ; Grussendorf M; Reiners C; Feldkamp J; Quadbeck B; Bockisch A; Schott M
    Med Klin (Munich); 2009 May; 104(5):343-8. PubMed ID: 19444414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
    N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodine therapy versus antithyroid medications for Graves' disease.
    Ma C; Xie J; Wang H; Li J; Chen S
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Graves' hyperthyroidism: present and future.
    Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
    Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
    Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
    Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
    Bartalena L
    J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease.
    Sawicka N; Sowiński J
    Endokrynol Pol; 2012; 63(1):10-3. PubMed ID: 22378091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total thyroidectomy for the treatment of recurrent graves' disease with ophthalmopathy.
    Nart A; Uslu A; Aykas A; Yuzbasioglu F; Dogan M; Demirtas O; Simsek C
    Asian J Surg; 2008 Jul; 31(3):115-8. PubMed ID: 18658008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tale of radioiodine and Graves' orbitopathy.
    Ponto KA; Zang S; Kahaly GJ
    Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.